Protein profiles distinguish stable and progressive chronic lymphocytic leukemia

Patients with a stable chronic lymphocytic leukemia (CLL) double their blood lymphocyte count in >5 years, but may develop progressive disease with lymphocytes doubling in <12 months. To identify a protein signature for progressive CLL, whole cell extracts of peripheral blood mononuclear cells...

Full description

Saved in:
Bibliographic Details
Published inLeukemia & lymphoma Vol. 57; no. 5; pp. 1033 - 1043
Main Authors Huang, Pauline Y., Mactier, Swetlana, Armacki, Natalie, Giles Best, O., Belov, Larissa, Kaufman, Kimberley L., Pascovici, Dana, Mulligan, Stephen P., Christopherson, Richard I.
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 03.05.2016
Subjects
Biomarkers, Tumor
Chromatography, Liquid
Chronic lymphocytic leukemia
Cluster Analysis
Disease Progression
Humans
Immunophenotyping
iTRAQ
Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell - metabolism
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
mass spectrometry
Neoplasm Staging
Phenotype
Prognosis
prognostic markers
Proteome
proteomics
Proteomics - methods
selected reaction monitoring
Tandem Mass Spectrometry
iTRAQ
mass spectrometry
Chronic lymphocytic leukemia
prognostic markers
proteomics
selected reaction monitoring
Online AccessGet full text

Cover

Abstract Patients with a stable chronic lymphocytic leukemia (CLL) double their blood lymphocyte count in >5 years, but may develop progressive disease with lymphocytes doubling in <12 months. To identify a protein signature for progressive CLL, whole cell extracts of peripheral blood mononuclear cells from patients with CLL (n = 27) were screened using iTRAQ (isobaric tags for relative and absolute quantification) analysis. A total of 84 differentially abundant proteins were identified from patients with stable and progressive CLL. Subsequently, 32 of these proteins were quantified by SRM (selected reaction monitoring) using extracts of purified CD19 + CLL cells from patients (n = 50). Hierarchical clustering of these protein profiles showed two clusters of patients that correlated with progressive and stable CLL, providing signatures that should be useful for triaging patients. Some of the proteins in the progressive cluster have not been linked with CLL, for example, glutamate dehydrogenase 1 and transcription intermediary factor 1-beta.
AbstractList Patients with a stable chronic lymphocytic leukemia (CLL) double their blood lymphocyte count in >5 years, but may develop progressive disease with lymphocytes doubling in <12 months. To identify a protein signature for progressive CLL, whole cell extracts of peripheral blood mononuclear cells from patients with CLL (n = 27) were screened using iTRAQ (isobaric tags for relative and absolute quantification) analysis. A total of 84 differentially abundant proteins were identified from patients with stable and progressive CLL. Subsequently, 32 of these proteins were quantified by SRM (selected reaction monitoring) using extracts of purified CD19 + CLL cells from patients (n = 50). Hierarchical clustering of these protein profiles showed two clusters of patients that correlated with progressive and stable CLL, providing signatures that should be useful for triaging patients. Some of the proteins in the progressive cluster have not been linked with CLL, for example, glutamate dehydrogenase 1 and transcription intermediary factor 1-beta.
Patients with a stable chronic lymphocytic leukemia (CLL) double their blood lymphocyte count in >5 years, but may develop progressive disease with lymphocytes doubling in <12 months. To identify a protein signature for progressive CLL, whole cell extracts of peripheral blood mononuclear cells from patients with CLL (n=27) were screened using iTRAQ (isobaric tags for relative and absolute quantification) analysis. A total of 84 differentially abundant proteins were identified from patients with stable and progressive CLL. Subsequently, 32 of these proteins were quantified by SRM (selected reaction monitoring) using extracts of purified CD19+ CLL cells from patients (n=50). Hierarchical clustering of these protein profiles showed two clusters of patients that correlated with progressive and stable CLL, providing signatures that should be useful for triaging patients. Some of the proteins in the progressive cluster have not been linked with CLL, for example, glutamate dehydrogenase 1 and transcription intermediary factor 1-beta.
Patients with a stable chronic lymphocytic leukemia (CLL) double their blood lymphocyte count in &gt;5 years, but may develop progressive disease with lymphocytes doubling in &lt;12 months. To identify a protein signature for progressive CLL, whole cell extracts of peripheral blood mononuclear cells from patients with CLL (n=27) were screened using iTRAQ (isobaric tags for relative and absolute quantification) analysis. A total of 84 differentially abundant proteins were identified from patients with stable and progressive CLL. Subsequently, 32 of these proteins were quantified by SRM (selected reaction monitoring) using extracts of purified CD19+ CLL cells from patients (n=50). Hierarchical clustering of these protein profiles showed two clusters of patients that correlated with progressive and stable CLL, providing signatures that should be useful for triaging patients. Some of the proteins in the progressive cluster have not been linked with CLL, for example, glutamate dehydrogenase 1 and transcription intermediary factor 1-beta.
Author Giles Best, O.
Huang, Pauline Y.
Pascovici, Dana
Mactier, Swetlana
Belov, Larissa
Armacki, Natalie
Kaufman, Kimberley L.
Christopherson, Richard I.
Mulligan, Stephen P.
Author_xml – sequence: 1
  givenname: Pauline Y.
  surname: Huang
  fullname: Huang, Pauline Y.
  organization: School of Molecular Bioscience, University of Sydney
– sequence: 2
  givenname: Swetlana
  surname: Mactier
  fullname: Mactier, Swetlana
  organization: School of Molecular Bioscience, University of Sydney
– sequence: 3
  givenname: Natalie
  surname: Armacki
  fullname: Armacki, Natalie
  organization: School of Molecular Bioscience, University of Sydney
– sequence: 4
  givenname: O.
  surname: Giles Best
  fullname: Giles Best, O.
  organization: Northern Blood Research Centre, Kolling Institute of Medical Research, Royal North Shore Hospital
– sequence: 5
  givenname: Larissa
  surname: Belov
  fullname: Belov, Larissa
  organization: School of Molecular Bioscience, University of Sydney
– sequence: 6
  givenname: Kimberley L.
  surname: Kaufman
  fullname: Kaufman, Kimberley L.
  organization: School of Molecular Bioscience, University of Sydney
– sequence: 7
  givenname: Dana
  surname: Pascovici
  fullname: Pascovici, Dana
  organization: Australian Proteome Analysis Facility, Macquarie University
– sequence: 8
  givenname: Stephen P.
  surname: Mulligan
  fullname: Mulligan, Stephen P.
  organization: Northern Blood Research Centre, Kolling Institute of Medical Research, Royal North Shore Hospital
– sequence: 9
  givenname: Richard I.
  surname: Christopherson
  fullname: Christopherson, Richard I.
  email: richard.christopherson@sydney.edu.au
  organization: School of Molecular Bioscience, University of Sydney
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26422656$$D View this record in MEDLINE/PubMed
BookMark eNp9kMlOwzAQQC0EolD4BFCOXFK8xalvIMQmVaKH3i3HGbeGxC52Aurfk6iFI6cZzbxZ9M7RsQ8eELoieMYIlrcEczonks8oJsVsqHAh6RE6I5jKnHLMjsec03yEJug8pXeMcSEFPUUTKjilohBnaLmMoQPns20M1jWQstqlzvl179ImS52uGsi0r8f-OkJK7gsys4nBO5M1u3a7CWbXjTn0H9A6fYFOrG4SXB7iFK2eHlcPL_ni7fn14X6RGyZElzPDwVhJCiaxqApZAqEVZ5ZiJq0glFg5rzAnpjQStJ7zoixLUxABNZeCsym62a8d_vrsIXWqdclA02gPoU-KlHMmCR_kDGixR00MKUWwahtdq-NOEaxGl-rXpRpdqoPLYe76cKKvWqj_pn7lDcDdHnDehtjq7xCbWnV614Roo_bGpXH_fzd-AGbJhUA
CitedBy_id crossref_primary_10_1038_s41598_021_82609_2
crossref_primary_10_3389_fimmu_2021_772304
crossref_primary_10_1002_mas_21550
crossref_primary_10_3390_cancers13143391
crossref_primary_10_1002_JLB_4HI0620_392R
crossref_primary_10_3109_10428194_2015_1121263
crossref_primary_10_1080_14789450_2017_1275967
Cites_doi 10.1158/1940-6207.CAPR-08-0153
10.1126/science.1248627
10.1056/NEJM199510193331606
10.1074/mcp.M114.044479
10.1073/pnas.101329598
10.1074/mcp.R500004-MCP200
10.4161/epi.24947
10.1006/bcmd.2000.0348
10.1387/ijdb.113336ld
10.1182/blood-2004-10-3999
10.4155/bio.12.246
10.3349/ymj.2009.50.3.399
10.3109/10428194.2013.867486
10.1038/43686
10.1111/j.1365-2141.2009.07979.x
10.1093/bioinformatics/btq054
10.1074/jbc.M005390200
10.1111/j.1365-2141.2009.07982.x
10.1186/ar3802
10.1111/j.1365-2354.2004.00489.x
10.1002/1097-0215(200002)9999:9999<::AID-IJC1037>3.0.CO;2-J
10.1021/pr5002803
10.1038/sj.leu.2401511
10.1016/j.gene.2013.09.052
10.1089/ars.2006.8.325
10.1016/S0962-8924(01)02153-5
10.1007/s00277-013-1883-1
10.1111/pcmr.12290
10.1007/s12032-012-0405-7
10.1021/pr5010828
10.1182/blood-2007-06-093906
10.1074/mcp.M300055-MCP200
10.1097/PAT.0b013e32835a0142
10.1182/blood.V118.21.1652.1652
10.1111/j.1582-4934.2008.00273.x
10.1016/j.exphem.2011.11.005
10.4155/bio.12.126
10.1182/blood.V94.6.1840
10.1037/0033-2909.85.1.185
10.1038/leu.2008.274
10.1016/j.leukres.2012.05.015
10.1016/j.lfs.2009.01.010
10.1016/j.molonc.2007.05.001
10.1182/blood-2011-04-351072
10.3322/caac.21208
10.1016/S0092-8674(00)00115-X
10.1016/0531-5565(94)00069-7
10.1074/mcp.M111.015370
10.1182/blood.V91.6.1845
10.1038/leu.2013.263
10.1182/blood-2013-11-539726
10.1016/j.clinbiochem.2009.08.003
10.1038/sj.leu.2403865
10.1002/cyto.b.20121
10.1182/blood-2006-08-043257
10.1182/blood.V124.21.4675.4675
10.1189/jlb.0709502
ContentType Journal Article
Copyright 2015 Taylor & Francis 2015
Copyright_xml – notice: 2015 Taylor & Francis 2015
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.3109/10428194.2015.1094692
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1029-2403
EndPage 1043
ExternalDocumentID 10_3109_10428194_2015_1094692
26422656
1094692
Genre Original Articles: Clinical
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
00X
03L
0BK
0R~
29L
36B
4.4
53G
5GY
AAJNR
AALUX
AAMIU
AAPUL
AAPXX
AAQRR
ABBKH
ABDBF
ABEIZ
ABLKL
ABPTK
ABUPF
ACENM
ACFUF
ACGEJ
ACGFS
ACLSK
ADCVX
ADFCX
ADRBQ
ADXPE
AECIN
AENEX
AEOZL
AEXWM
AEYQI
AFKVX
AFWLO
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AJWEG
AKBVH
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AMDAE
BABNJ
BLEHA
BOHLJ
CCCUG
CS3
DKSSO
DU5
EAP
EBB
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
H13
HZ~
J.N
KRBQP
KSSTO
KWAYT
KYCEM
LGLTD
M4Z
O9-
P2P
RNANH
RVRKI
SV3
TFDNU
TFL
TFW
TUS
UEQFS
V1S
~1N
5VS
AALIY
AAORF
ABLIJ
ABWCV
ABXYU
ABZEW
ACIEZ
ACKZS
ADFOM
ADFZZ
AEIIZ
AFLEI
AJVHN
ALYBC
AWYRJ
BRMBE
CAG
CGR
COF
CUY
CVF
CYYVM
CZDIS
DRXRE
DWTOO
ECM
EIF
HF~
JENTW
LJTGL
M44
NPM
NUSFT
QQXMO
TBQAZ
TDBHL
TERGH
TUROJ
UDS
Y6R
ZGI
ZXP
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c366t-3c4ecf9153906b597e12b43f2039f6121f98b041c7c9eaa845777c516ed49643
ISSN 1042-8194
IngestDate Thu Oct 24 23:44:11 EDT 2024
Thu Nov 21 23:41:12 EST 2024
Wed Oct 16 00:53:40 EDT 2024
Tue Jun 13 19:49:23 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords iTRAQ
mass spectrometry
Chronic lymphocytic leukemia
prognostic markers
proteomics
selected reaction monitoring
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c366t-3c4ecf9153906b597e12b43f2039f6121f98b041c7c9eaa845777c516ed49643
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 26422656
PQID 1783914201
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_1783914201
pubmed_primary_26422656
informaworld_taylorfrancis_310_3109_10428194_2015_1094692
crossref_primary_10_3109_10428194_2015_1094692
PublicationCentury 2000
PublicationDate 2016-05-03
PublicationDateYYYYMMDD 2016-05-03
PublicationDate_xml – month: 05
  year: 2016
  text: 2016-05-03
  day: 03
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Leukemia & lymphoma
PublicationTitleAlternate Leuk Lymphoma
PublicationYear 2016
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References 26726799 - Leuk Lymphoma. 2016 May;57(5):985-6
27096890 - Leuk Lymphoma. 2016 May;57(5):987-90
26674387 - Leuk Lymphoma. 2016 May;57(5):I
Vidal L (CIT0004) 2012; 9
CIT0030
CIT0032
CIT0034
CIT0033
CIT0036
CIT0035
CIT0038
CIT0037
CIT0039
CIT0041
CIT0040
CIT0043
CIT0042
CIT0001
Otake Y (CIT0013) 2007; 109
Benjamini Y (CIT0020) 1995; 57
CIT0003
CIT0047
CIT0002
CIT0005
CIT0049
CIT0048
CIT0007
CIT0006
CIT0009
CIT0008
CIT0050
CIT0052
CIT0051
CIT0010
Damle RN (CIT0044) 1999; 94
CIT0054
CIT0053
CIT0012
CIT0056
CIT0011
CIT0055
Gupta P (CIT0046) 2011; 118
CIT0014
CIT0058
CIT0057
CIT0016
CIT0015
CIT0059
CIT0018
CIT0017
CIT0019
CIT0021
CIT0023
Yokoyama A (CIT0045) 1998; 91
CIT0022
Puiggros A (CIT0031) 2014; 124
CIT0025
CIT0024
CIT0027
CIT0026
CIT0029
CIT0028
References_xml – ident: CIT0006
  doi: 10.1158/1940-6207.CAPR-08-0153
– ident: CIT0055
  doi: 10.1126/science.1248627
– ident: CIT0003
  doi: 10.1056/NEJM199510193331606
– ident: CIT0011
  doi: 10.1074/mcp.M114.044479
– ident: CIT0039
  doi: 10.1073/pnas.101329598
– ident: CIT0034
  doi: 10.1074/mcp.R500004-MCP200
– ident: CIT0028
  doi: 10.4161/epi.24947
– ident: CIT0037
  doi: 10.1006/bcmd.2000.0348
– ident: CIT0056
  doi: 10.1387/ijdb.113336ld
– ident: CIT0048
  doi: 10.1182/blood-2004-10-3999
– ident: CIT0030
  doi: 10.4155/bio.12.246
– ident: CIT0049
  doi: 10.3349/ymj.2009.50.3.399
– ident: CIT0029
  doi: 10.3109/10428194.2013.867486
– ident: CIT0038
  doi: 10.1038/43686
– ident: CIT0010
  doi: 10.1111/j.1365-2141.2009.07979.x
– ident: CIT0021
  doi: 10.1093/bioinformatics/btq054
– ident: CIT0040
  doi: 10.1074/jbc.M005390200
– ident: CIT0032
  doi: 10.1111/j.1365-2141.2009.07982.x
– ident: CIT0058
  doi: 10.1186/ar3802
– ident: CIT0002
  doi: 10.1111/j.1365-2354.2004.00489.x
– ident: CIT0008
  doi: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1037>3.0.CO;2-J
– ident: CIT0054
  doi: 10.1021/pr5002803
– ident: CIT0014
  doi: 10.1038/sj.leu.2401511
– volume: 57
  start-page: 289
  year: 1995
  ident: CIT0020
  publication-title: J Roy Stat Soc Series B Method
  contributor:
    fullname: Benjamini Y
– ident: CIT0024
  doi: 10.1016/j.gene.2013.09.052
– ident: CIT0059
  doi: 10.1089/ars.2006.8.325
– ident: CIT0053
  doi: 10.1016/S0962-8924(01)02153-5
– ident: CIT0025
  doi: 10.1007/s00277-013-1883-1
– ident: CIT0016
  doi: 10.1111/pcmr.12290
– ident: CIT0026
  doi: 10.1007/s12032-012-0405-7
– ident: CIT0017
  doi: 10.1021/pr5010828
– ident: CIT0018
  doi: 10.1182/blood-2007-06-093906
– ident: CIT0009
  doi: 10.1074/mcp.M300055-MCP200
– ident: CIT0012
  doi: 10.1097/PAT.0b013e32835a0142
– volume: 118
  start-page: 1652
  year: 2011
  ident: CIT0046
  publication-title: Blood
  doi: 10.1182/blood.V118.21.1652.1652
  contributor:
    fullname: Gupta P
– ident: CIT0047
  doi: 10.1111/j.1582-4934.2008.00273.x
– ident: CIT0051
  doi: 10.1016/j.exphem.2011.11.005
– ident: CIT0015
  doi: 10.4155/bio.12.126
– volume: 94
  start-page: 1840
  year: 1999
  ident: CIT0044
  publication-title: Blood
  doi: 10.1182/blood.V94.6.1840
  contributor:
    fullname: Damle RN
– ident: CIT0022
  doi: 10.1037/0033-2909.85.1.185
– ident: CIT0041
  doi: 10.1038/leu.2008.274
– ident: CIT0027
  doi: 10.1016/j.leukres.2012.05.015
– ident: CIT0043
  doi: 10.1016/j.lfs.2009.01.010
– ident: CIT0005
  doi: 10.1016/j.molonc.2007.05.001
– ident: CIT0042
  doi: 10.1182/blood-2011-04-351072
– ident: CIT0001
  doi: 10.3322/caac.21208
– ident: CIT0052
  doi: 10.1016/S0092-8674(00)00115-X
– ident: CIT0036
  doi: 10.1016/0531-5565(94)00069-7
– volume: 9
  start-page: 1
  year: 2012
  ident: CIT0004
  publication-title: Cochrane Database of Systematic Reviews
  contributor:
    fullname: Vidal L
– ident: CIT0007
  doi: 10.1074/mcp.M111.015370
– volume: 91
  start-page: 1845
  year: 1998
  ident: CIT0045
  publication-title: Blood
  doi: 10.1182/blood.V91.6.1845
  contributor:
    fullname: Yokoyama A
– ident: CIT0023
  doi: 10.1038/leu.2013.263
– ident: CIT0035
  doi: 10.1182/blood-2013-11-539726
– ident: CIT0057
  doi: 10.1016/j.clinbiochem.2009.08.003
– ident: CIT0033
  doi: 10.1038/sj.leu.2403865
– ident: CIT0019
  doi: 10.1002/cyto.b.20121
– volume: 109
  start-page: 3069
  year: 2007
  ident: CIT0013
  publication-title: Blood
  doi: 10.1182/blood-2006-08-043257
  contributor:
    fullname: Otake Y
– volume: 124
  start-page: 4675
  year: 2014
  ident: CIT0031
  publication-title: Blood
  doi: 10.1182/blood.V124.21.4675.4675
  contributor:
    fullname: Puiggros A
– ident: CIT0050
  doi: 10.1189/jlb.0709502
SSID ssj0005962
Score 2.2243662
Snippet Patients with a stable chronic lymphocytic leukemia (CLL) double their blood lymphocyte count in >5 years, but may develop progressive disease with lymphocytes...
Patients with a stable chronic lymphocytic leukemia (CLL) double their blood lymphocyte count in &gt;5 years, but may develop progressive disease with...
SourceID proquest
crossref
pubmed
informaworld
SourceType Aggregation Database
Index Database
Publisher
StartPage 1033
SubjectTerms Biomarkers, Tumor
Chromatography, Liquid
Chronic lymphocytic leukemia
Cluster Analysis
Disease Progression
Humans
Immunophenotyping
iTRAQ
Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell - metabolism
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
mass spectrometry
Neoplasm Staging
Phenotype
Prognosis
prognostic markers
Proteome
proteomics
Proteomics - methods
selected reaction monitoring
Tandem Mass Spectrometry
Title Protein profiles distinguish stable and progressive chronic lymphocytic leukemia
URI https://www.tandfonline.com/doi/abs/10.3109/10428194.2015.1094692
https://www.ncbi.nlm.nih.gov/pubmed/26422656
https://search.proquest.com/docview/1783914201
Volume 57
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdKJyFeJr4pXzISbyglthMneVyBUSE29lCk8RQ5ji1VlBRtidD4M_iLuYud1kNlYrxEkZVcnNwv5zv77mdCXla5YUxbHklrZZSkXEV5kqqI2yKLq7wWusYV3aNjOf-cfDhNT0ejX0HWUtdWU_1zZ13J_2gV2kCvWCV7Dc1uhEIDnIN-4QgahuM_6fgESRaWfZIV8iud43ILpjF3SFMEbh9WRTkigHUfVmOWkHZsuK9WF6DHtb5AwtaV6b6ab0sVeqoffVuPDXfx1oTPOz_NjImF6Kd-mQZT2-3S7-b1w7Qr1agAVEq7bbKPcdZouQHV-773M-MKUD5Nw7kIJvvMPxGYTyz2AR_DTREY38b7NRwR2lxHSu2xlQYGlMWOF8MPxiBQ7DL0wvGk4vPwcZiilyIzFgT7fDuyDav5fwx4mzRECIBQUDmIKVFM6cXcIHtIrpiMyd7B7O3scJs4VEi3hu7f1dWFoaDXO_tzyeO5xIf796im924Wt8m-D0vogcPYHTIyzV1y88gnXtwjJx5qdIAaDaBGHdQoQI0GUKMeajSAGh2gdp8sDt8t3swjvxlHpIWUbSR0YrQtYIAsYllBGGoYrxJheSwKizR0tsirOGE604VRCn74LMt0yqSpE-R8e0DGzboxjwjNOUR0ItO6limSG6maF9xUubSizhg3EzIdvlf53VGulFdqakKK8KuWbT_XZd3GNHjflfe-GFRQgmHF1TLVmHV3XrIMYgeWwMUT8tDpZtMdiCIgbEnl4-t29Qm5tf1vnpJxe9aZZ-DVttVzD7PfYoaY0g
link.rule.ids 314,780,784,27924,27925
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protein+profiles+distinguish+stable+and+progressive+chronic+lymphocytic+leukemia&rft.jtitle=Leukemia+%26+lymphoma&rft.au=Huang%2C+Pauline+Y.&rft.au=Mactier%2C+Swetlana&rft.au=Armacki%2C+Natalie&rft.au=Giles+Best%2C+O.&rft.date=2016-05-03&rft.issn=1042-8194&rft.eissn=1029-2403&rft.volume=57&rft.issue=5&rft.spage=1033&rft.epage=1043&rft_id=info:doi/10.3109%2F10428194.2015.1094692&rft.externalDBID=n%2Fa&rft.externalDocID=10_3109_10428194_2015_1094692
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1042-8194&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1042-8194&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1042-8194&client=summon